These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 21829021

  • 1. Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
    Kim HY, Park JW.
    Dig Dis; 2011; 29(3):303-9. PubMed ID: 21829021
    [Abstract] [Full Text] [Related]

  • 2. Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
    Zhu AX.
    Expert Opin Investig Drugs; 2010 May; 19(5):663-72. PubMed ID: 20367287
    [Abstract] [Full Text] [Related]

  • 3. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 4. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA, Galle PR.
    Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
    [Abstract] [Full Text] [Related]

  • 5. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
    Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, Bolondi L.
    Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):391-8. PubMed ID: 19940784
    [Abstract] [Full Text] [Related]

  • 6. AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
    Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA.
    Onkologie; 2011 Apr; 34(10):538-42. PubMed ID: 21985853
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
    Kudo M, Ueshima K.
    Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
    [Abstract] [Full Text] [Related]

  • 9. Systemic treatment of hepatocellular carcinoma: dawn of a new era?
    Zhu AX.
    Ann Surg Oncol; 2010 May; 17(5):1247-56. PubMed ID: 20405329
    [Abstract] [Full Text] [Related]

  • 10. The present and the future landscape of treatment of advanced hepatocellular carcinoma.
    Rimassa L, Santoro A.
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S273-80. PubMed ID: 20547314
    [Abstract] [Full Text] [Related]

  • 11. A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
    Song T, Zhang W, Wu Q, Kong D, Ma W.
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1233-8. PubMed ID: 21941188
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Jan; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, Wang D, Gao H.
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [Abstract] [Full Text] [Related]

  • 15. Systemic therapy of hepatocellular carcinoma: are we making progress?
    Roxburgh P, Evans TR.
    Adv Ther; 2008 Nov; 25(11):1089-104. PubMed ID: 18972075
    [Abstract] [Full Text] [Related]

  • 16. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
    Cabibbo G, Rolle E, De Giorgio M, Genco C, Pressiani T, Spada F, Sacco R, HCC Working Group.
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
    [Abstract] [Full Text] [Related]

  • 17. Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
    Kudo M.
    Dig Dis; 2011 Dec; 29(3):289-302. PubMed ID: 21829020
    [Abstract] [Full Text] [Related]

  • 18. Novel molecular therapies in hepatocellular carcinoma.
    Faivre S, Bouattour M, Raymond E.
    Liver Int; 2011 Jan; 31 Suppl 1():151-60. PubMed ID: 21205154
    [Abstract] [Full Text] [Related]

  • 19. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
    Lord R, Suddle A, Ross PJ.
    Int J Clin Pract; 2011 Feb; 65(2):182-8. PubMed ID: 21235699
    [Abstract] [Full Text] [Related]

  • 20. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R, Byrne MT, Tan A, Aucejo F.
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.